glp 1 blue cross blue shield Why we are changing coverage of GLP-1 drugs for weight loss blue cross blue shield fep

This lower appetite can be helpful if overeating was a major struggle before

Another phase III, randomized, open-label, non-inferiority, head-to-head trial, AWARD-6, evaluated dulaglutide (1.5 mg) versus liraglutide (1.8 mg) in patients with T2DM

GLP-1-based therapies for diabetes contribute to reduce inflammation and have additional beneficial effects such as islet preservation and improvement of insulin sensitivity in addition to glucose-lowering effects

Stay in touch about special discounts, nutrition tips and additional education

Their comparison offers insight into how two drugs with the same fundamental mechanism can be differentiated through clinical development strategy, formulation, and positioning